Allele-Specific Methylation of SPDEF: A Novel Moderator of Psychosocial Stress and Substance Abuse

Nicole Tay, M.Sc., Christine Macare, Ph.D., Yun Liu, Ph.D., Barbara Ruggeri, Ph.D., Tianye Jia, Ph.D., Congying Chu, Ph.D., Francesca Biondo, Ph.D., Alex Ing, Ph.D., Qiang Luo, Ph.D., Daniil Sarkysian, Ph.D., Tobias Banaschewski, M.D., Ph.D., Gareth J. Barker, Ph.D., Arun L.W. Bokde, Ph.D., Uli Bromberg, Ph.D., Christian Büchel, M.D., Erin Burke Quinlan, Ph.D., Sylvane Desrivières, Ph.D., Herta Flor, Ph.D., Vincent Frouin, Ph.D., Hugh Garavan, Ph.D., Penny Gowland, Ph.D., Andreas Heinz, M.D., Ph.D., Bernd Ittermann, Ph.D., Jean-Luc Martinot, M.D., Ph.D., Eric Artiges, M.D., Ph.D., Frauke Nees, Ph.D., Dimitri Papadopoulos Orfanos, Ph.D., Tomáš Paus, M.D., Ph.D., Luise Poustka, M.D., Sarah Hohmann, M.D., Juliane H. Fröhner, M.Sc., Michael N. Smolka, M.D., Henrik Walter, M.D., Ph.D., Robert Whelan, Ph.D., Helge Frieling, M.D., Ph.D., Stefan Bleich, M.D., Ph.D., Edward D. Barker, Ph.D., Ann-Christine Syvänen, Ph.D., Joëlle Rüegg, Ph.D., Tomas J. Ekström, Ph.D., Georgy Bakalkin, Ph.D., Gunter Schumann, M.D., and the IMAGEN Consortium

Objective: Psychosocial stress is a key risk factor for substance abuse among adolescents. Recently, epigenetic processes such as DNA methylation have emerged as potential mechanisms that could mediate this relationship. The authors conducted a genome-wide methylation analysis to investigate whether differentially methylated regions are associated with psychosocial stress in an adolescent population.

Methods: A methylome-wide analysis of differentially methylated regions was used to examine a sample of 1,287 14-year-old adolescents (50.7% of them female) from the European IMAGEN study. The Illumina 450k array was used to assess DNA methylation, pyrosequencing was used for technical replication, and linear regression analyses were used to identify associations with psychosocial stress and substance use (alcohol and tobacco). Findings were replicated by pyrosequencing a test sample of 413 participants from the IMAGEN study.

Environmental stressors are linked to the onset of psychiatric symptoms (1), many of which emerge during adolescence (2). For example, repeated exposure to severe adversity—such as childhood maltreatment or peer victimization—is associated with increased risk for substance abuse in adolescents (3). Even more common psychosocial stressors (such as problems in relationships, problems at school, and parental divorce) can influence adolescents' propensity to substance abuse later in life (4). Although the importance of environmental factors is well understood, the biological mechanisms that underlie their effects on substance abuse, and their genetic interactions, are poorly characterized.

Recently, variability in DNA methylation—an epigenetic process regulating gene expression (5)—has emerged as a

Results: Hypermethylation in the sterile alpha motif/pointed domain containing the ETS transcription factor (*SPDEF*) gene locus was associated with a greater number of stressful life events in an allele-dependent way. Among individuals with the minor G-allele, *SPDEF* methylation moderated the association between psychosocial stress and substance abuse. *SPDEF* methylation interacted with lifetime stress in gray matter volume in the right cuneus, which in turn was associated with the frequency of alcohol and tobacco use. *SPDEF* was involved in the regulation of *trans*-genes linked to substance use.

Conclusions: Taken together, the study findings describe a novel epigenetic mechanism that helps explain how psychosocial stress exposure influences adolescent substance abuse.

Am J Psychiatry 2019; 176:146-155; doi: 10.1176/appi.ajp.2018.17121360

potential mechanism by which environmental adversity could translate into vulnerability to developing substance use among adolescents (6). It has been established that DNA methylation is sensitive to environmental influences, such as psychosocial adversity (7), that DNA methylation can be affected by genetic influences, as demonstrated by allelespecific methylation (8), and that aberrant DNA methylation patterns are linked to a range of psychopathologies, including substance abuse (9). Together, these findings give rise to the hypothesis that the effect of environmental influences on psychiatric symptoms and disorders may be mediated by variations in DNA methylation. However, there is insufficient empirical evidence to confirm or reject this hypothesis.

See related features: Editorials by Dr. Brady (p. 87) and Dr. Pollock and Dr. Lossie (p. 92) and AJP Audio (online)

Furthermore, while recent studies have reported altered methylation patterns of toll-like receptor 4 (*TLR4*) (10), monoamine oxidase (*MAO*) (11), and glucocorticoid receptor genes in relation to substance use disorders (12), including drinking and smoking, these studies mainly focused on candidate genes. A methylome-wide analysis, in contrast, can provide a hypothesis-free platform, thus potentially identifying genes that point toward novel biological pathways (13).

We therefore carried out a genome-wide methylation analysis of psychosocial stress in adolescents and investigated its relationship to substance abuse. By using data from the population-based IMAGEN study (14), we measured DNA methylation from whole blood, assessed the frequency of stressful life events in the past year, and quantified lifetime substance use. To analyze the association between stress and DNA methylation, we applied a genome-wide region-based approach (15) that increases sensitivity to detect CpG clusters with greater biological relevance by taking into account the high correlation of methylation profiles in neighboring CpG sites (16). Lastly, we investigated the effect of singlenucleotide polymorphisms (SNPs) on methylation, examined the relationship between methylation and cis-gene and transgene expression, and analyzed the relationship between methylation and brain structure.

METHODS

Participants

A total of 1,700 participants from the IMAGEN cohort were randomly assigned to an exploration sample (N=1,287) or a test sample (N=413) with similar demographic characteristics for replication (female, 53.3%; mean age, 14.44 years [SD=0.45]). IMAGEN is a European multicenter imaginggenetics study of adolescents recruited from England, France, Ireland, and Germany (14). All data from the IMAGEN study are available online (https://imagen2.cea.fr).

Questionnaire and Interview Data

Negative stressful life events. An adapted version of the Life Events Questionnaire (17), a 39-item tool, was used to assess life events of individuals in the IMAGEN cohort during adolescence (for further details, see the online supplement). Given that the neurobiological effects of stress depend on the age at onset, we focused on the frequency of negative stressful life events that occurred in the past year only as a measure of interest.

Substance use. The European School Survey Project on Alcohol and Other Drugs questionnaire (18) was used to assess the frequency of lifetime smoking, lifetime alcohol use, and lifetime binge drinking (for further details, see the online supplement).

Methylation, Genetic, and Gene Expression Data

Methylation. DNA was extracted from whole blood samples and bisulphite treated using the EZ 96 DNA methylation kit (Zymo Research, Irvine, Calif.). DNA methylation

was quantified with the Illumina Infinium Human-Methylation450 BeadChip (19) run on an Illumina HiScan System (Illumina, San Diego) using the manufacturer's standard protocol. Pyrosequencing was carried out for technical validation and independent replication with a PSQ96 genetic sequencer using PyroMark Gold Q96 reagents (Qiagen, Valencia, Calif.) in accordance with the manufacturer's recommendations (for further details, see the online supplement).

Genetic. Genotype data were collected for 582,982 markers using DNA extracted from whole blood, as previously described, as well as the Illumina HumanHap610 Genotyping BeadChip. Genotype data were coded as the number of major alleles (for details on quality control, see the online supplement).

Gene expression. Total RNA was extracted from whole blood cells collected from participants at age 14 using the PAXgene Blood RNA Kit (Qiagen, Valencia, Calif.) (for further details, see the online supplement). Gene expression profiling was performed using Illumina HumanHT-12, version 4, Expression BeadChips (Illumina, San Diego).

MRI Data Acquisition and Preprocessing

Structural data were acquired at eight IMAGEN assessment sites with 3-T MRI scanners (Siemens, Munich; Philips, Amsterdam; and General Electric, Boston). Full details of MRI acquisition protocols and quality control checks, including standardization across MRI scanners, have been published elsewhere (14). Details of the preprocessing are provided in the online supplement.

Data Analysis

All analyses controlled for the effects of recruitment site, gender, and cell count (for further details, see the online supplement). Analyses involving life events controlled for emotional valence to ensure that effects were linked to frequency rather than subjective perception. Analyses involving methylation data were controlled for acquisition waves (for further details, see the online supplement). All analyses were performed with SPSS, version 20.0 (IBM, Armonk, N.Y. [20]) or R, version 3.1.3 (https://cran.r-project.org), unless indicated otherwise. For all analyses, a significance threshold set at <0.05 was applied. Pearson's correlation coefficient (r) is reported, except as otherwise indicated.

Identification of differentially methylated regions. Data collected using the Illumina Infinium HumanMethylation450 BeadChip were analyzed with the minfi package in the Bioconductor software suite (21). Methylation data underwent quality control (for further details, see the online supplement) and were preprocessed using the stratified quantile normalization implemented in minfi (21). The *bumphunter* function in minfi R (15) was used to identify clusters of neighboring CpGs differentially methylated with psychosocial stress (see the online supplement). Post hoc quality control was conducted to exclude SNPs located

TABLE 1. Descriptive data for the study participants in a methylome-wide analysis of psychosocial stress and *SPDEF*^a

| Variable | Ν | Mean | SD | Minimum | Maximum |
|--|-------|--------|------|---------|---------|
| Behavioral data | | | | | |
| Frequency of negative stressful life events in the past year | 1,213 | 2.80 | 1.78 | 0 | 10 |
| Emotional valence European School Survey Project on Alcohol and Other Drugs questionnaire | 1,213 | -16.65 | 4.62 | -27 | 4 |
| Lifetime smoking | 1,275 | 0.87 | 1.70 | 0 | 6 |
| Lifetime alcohol use | 1,272 | 2.01 | 1.73 | 0 | 6 |
| Lifetime binge drinking | 1,272 | 0.63 | 1.24 | 0 | 5 |
| Genetic data Methylation | | | | | |
| Mean SPDEF | 1,287 | 0.45 | 0.26 | 0.10 | 0.83 |
| SPDEF cg16527629 | 1,287 | 0.34 | 0.24 | 0.06 | 0.84 |
| SPDEF cg01395541 | 1,287 | 0.57 | 0.28 | 0.13 | 0.92 |
| Single-nucleotide polymorphism Genotype | | | | | |
| rs2233632 | 1,112 | 1.37 | 0.66 | | |
| GG | 114 | | | | |
| GA | 468 | | | | |
| AA | 530 | | | | |
| rs2233631 | 1,112 | 1.38 | 0.66 | | |
| GG | 114 | | | | |
| GA | 467 | | | | |
| AA | 531 | | | | |
| Gene expression Illumina HumanHT–12 Version 4 Expression BeadChips | 660 | | | | |
| Neuroimaging data T1 gray matter | 512 | | | | |

under the probe that may affect the stability of the probe's hybridization and its extension efficiency (22).

Gene-environment interaction analysis. A general linear model was used to examine between-subject effects of genotype, frequency of negative stressful life events, and their interaction with methylation. Effect size is reported as Cohen's d.

Stress, methylation, and substance use. Separate multiple regression models were used to establish the relationship between psychosocial stress, methylation, and substance use. A one-tailed test was used for the analyses between methylation and substance use. A total of 10,000 permutations were applied to correct for multiple testing.

Stress-methylation interaction analysis. General linear models were used to examine the effect of the frequency of negative stressful life events, methylation, and their interaction with substance use and gray matter volumes independently.

Gray matter volume and substance use. A group comparison between participants with a high frequency of combined drinking and smoking and participants who did not consume

Blood-brain methylation association. The Blood Brain DNA Methylation Comparison Tool (http://epigenetics.iop.kcl.ac.uk/bloodbrain) was used to examine the consistency of methylation across blood and brain (23) (for further details, see the online supplement).

Methylation-expression quantitative trait loci analyses. The methylation-expression quantitative trait loci (eQTL) model was performed using the Matrix eQTL R package (24), and the database for annotation, visualization, and integrated discovery (DAVID) (25) was used to determine enrichment of biological processes and disease classes (for further details, see the online supplement). Only individuals with both methylation and gene expression data were included in the analyses (N=277).

Intra- and interchromosomal interactions between the SPDEF and trans-genes. To determine the physical associations between the *SPDEF* promoter region and the differentially expressed *trans*-genes, the Hi-C browser for SKNMC cells (http://promoter.bx.psu. edu/hi-c/index.html) was used to examine the intra- and interchromosomal interactions (26).

RESULTS

Association of Differentially Methylated Regions With Frequency of Stressful Life Events

Genome-wide DNA methylation was assessed in 1,287 adolescents (50.7% of them female; mean age, 14.45 years [SD=0.63]) using the Illumina 450k array (Table 1). Genome-wide analysis was conducted to identify differentially methylated regions associated with the frequency of negative stressful life events (for further details, see the online supplement). We found a genome-wide significant differentially methylated region ($p=4.16 \times 10^{-6}$; family-wise error-corrected p=0.018) located in the 5' region of the sterile alpha motif/pointed domain epithelial specific transcription factor (SPDEF) gene (Table 2). Within this SPDEF region, we identified two CpG sites (cg16527629 and cg01395541) that were both significantly associated with the frequency of stress (r=0.094, df=1201, p=0.001 and r=0.082, df=1201, p=0.004, respectively). These CpG sites contained SNPs rs2233632 (0 bp) and rs2233631 (2 bp), respectively (Figure 1). To validate the 450k data, we carried out pyrosequencing analysis for both CpG sites in 94 individuals and found high correlations of methylation

| TABLE 2. Results from bum | o hunting in a methylo | ome-wide analysis of p | osychosocial stress and SPDEF |
|---------------------------|------------------------|------------------------|-------------------------------|
|---------------------------|------------------------|------------------------|-------------------------------|

| C | | | Compositored | | CpG Sites Located Within Differentially | | Allele-Specific Frequencies and Methylation Levels | | |
|---|-----|-----------------------|--------------|-----------------|--|-----------|---|--|--|
| Symbol) | Chr | р | p | Location | Region | SNPs | GG | GA | AA |
| Sterile alpha motif/ pointed domain containing ETS transcription factor (SPDEF) | 6 | 4.16×10 ⁻⁶ | 0.018 | Promoter | Cg01395541 | rs2233631 | 8.9%, N=114, M=0.82, SD=0.02 | 36.3%, N=467, M=0.83, SD=0.04 | 41.3%, N=531, M=0.27, SD=0.08 |
| | | | | | Cg16527629 | rs2233632 | 8.9%, N=114, M=0.77, SD=0.07 | 36.4%, N=468, M=0.48, SD=0.04 | 41.2%, N=530, M=0.10, SD=0.03 |
| Hook microtubule tethering protein 2 (HOOK2) | 19 | 4.86×10 ⁻⁶ | 0.021 | Covers exons | Cg04657146 Cg06417478 Cg11738485 Cg23899408 | | | | |

levels (cg01395541: r=0.85, p= 2.21×10^{-37} ; cg16527629: r=0.82, p= 6.77×10^{-24}) (for further details, see the online supplement) consistent with previous comparisons (27). An investigation of the *SPDEF* sequence revealed that the CpG site cg01395543 harbored the binding motif of the transcription factor YY1, GCAT/CCAT: TTGGTGGTGG GTACCTCTGTCCT**GC**[**A**/G]**T**GGCATCCCTG**CCAT**CACC CTTTGG.

We identified an additional differentially methylated region in the hook microtubule-tethering protein 2 (*HOOK2*) gene but excluded it from further analyses because it contained SNPs located at the probe binding site, and this could have resulted in false DNA methylation signals (for further details, see the online supplement).

Genetic control of methylation levels. To determine the effect of SNP genotype on methylation at each CpG site, we examined the allele-specific methylation levels. We found that methylation levels for GG and GA were higher than the levels for the frequent homozygotes (Table 2). In addition, we found that the frequency of alleles at rs2233632 and rs2233631 was significantly associated with methylation levels at the respective CpG sites cg16527629 and cg01395541 (r=-0.982, p $<2.2 \times 10^{-16}$ and r=-0.876, p $<2.2 \times 10^{-16}$). Thus, the main association previously observed between stress and methylation was at least in part dependent on genotype.

Interaction between genotype, stress, and methylation. Because methylation levels at CpG sites cg01395541 and cg16527629 are genotype dependent, we tested whether methylation was exclusively under genetic control or whether there was a gene-environment interaction with methylation at each CpG site. We found a significant interaction between the frequency of stressful life events and rs2233631 genotypes associated with methylation levels at cg01395541 (T=2.831, Cohen's d=0.174, p=0.005, two-tailed), indicating that the level of methylation at cg01395541 was dependent on both genotype and stress exposure. An interaction was not observed for cg16527629 (p=0.338), indicating that the methylation levels observed were entirely the result of a SNP effect. We therefore excluded cg16527629 from further analysis.

When the SNP rs2233631 carries the G allele, the sequence (5'-TGCGTGGCAT-3') contains a CpG site that can potentially be methylated. However, when rs2233631 carries the A allele, the CpG site is abrogated in the sequence (5'-TGCATGGCAT-3'), resulting in an absence of methylation. Hence, we repeated the analyses in the remaining SNP genotypes (GA and GG) (Figure 2A). We found that the effect size of the interaction between the frequency of stressful life events and rs2233631 genotypes (GA and GG) with methylation levels at cg01395541 increased by 18% (T=2.403, Cohen's d=0.205, p=0.017, two-tailed) upon removal of AA homozygotes.

Because DNA methylation is known to be a dynamic epigenetic mark, we also investigated the effect of lifetime stress on cg01395541 methylation. We did not find a significant interaction of lifetime stress and genotype with methylation (T=1.420, p=0.156), suggesting that cg01395541 methylation was due to the accumulation of stress within the past year and not compounded by lifetime stress exposure.

Independent replication of interaction between stress and genotype with methylation. To replicate our interaction findings, we used bisulfite pyrosequencing to assess methylation levels for *SPDEF* cg01395541 in a test sample of 413 individuals from the IMAGEN study. We replicated the interaction between stress and rs2233631 SNP genotypes (GA and GG) with methylation levels at the CpG site cg01395541 (T=2.239, p=0.013). A meta-analysis of the exploratory and replication samples showed an interaction between stress and SNP genotype with methylation levels at cg01395541 (Z=3.195, p=0.0014, two-tailed).





^a Configured using the Santa Cruz Genomics Institute Genome Browser, build GRCh37/hg19 (https://genome. ucsc.edu).

Integrating *SPDEF* Methylation, Stress, and Substance Use

Associations between stress and substance use. To investigate the relationship between psychosocial adversity and substance abuse in the IMAGEN sample, we examined the association between stress and substance use in all genotypes. We found that the frequency of negative stressful life events was positively associated with lifetime smoking (r=0.21, $r^2=0.0441$, $p=2.07\times10^{-13}$), lifetime alcohol consumption (r=0.16, $r^2=0.0256$, $p=1.64\times10^{-8}$), and lifetime binge drinking (r=0.14, $r^2=0.0196$, $p=6.81\times10^{-7}$).

Stratifying by genotype, we found stronger associations between the frequency of negative stressful life events and lifetime alcohol consumption ($r^2=0.0303$, $p=5.3\times10^{-5}$) and lifetime binge drinking ($r^2=0.0234$, $p=3.92\times10^{-4}$) in carriers of the G allele compared with AA homozygotes, suggesting that G-allele carriers are more susceptible to developing alcohol abuse as a result of psychosocial stress exposure. No such difference was observed for lifetime smoking ($r^2=0.0437$, $p=1.04\times10^{-6}$).

Associations between methylation and substance use. Next, we sought to determine the relationship between methylation and substance use problems by assessing the association between methylation levels at site cg01395541 and drinking and smoking behaviors. Methylation levels at cg01395541 were positively associated with lifetime binge drinking (r=0.099, p=0.008; permutation-based p=0.0228), and an association with lifetime smoking fell just short of statistical significance (r=0.087, p=0.020; permutation-based p=0.0507); the association with lifetime alcohol consumption was not significant (p=0.268).

Interaction of stress and methylation with substance use. Because we found separate main effects of stress and methylation on substance use, we hypothesized that cg01395541 methylation influenced the link between psychosocial stress and drinking and smoking behaviors. We observed a significant interaction between the frequency of negative stressful life events and cg01395541 methylation levels with lifetime binge drinking (T=2.274, df=541, p=0.023, two-tailed) (Figure 2B). When comparing the variance analysis (for further details, see the online supplement). No interaction was observed for lifetime smoking (p=0.118, two-tailed).

explained by the two models

(the model with main effects only and the model includ-

ing the interactions), we

found that the model that

included the interactions

explained significantly more

variance (partial r²=0.0256,

p=0.00837), suggesting that

methylation at cg01395541

moderates the association

between stress and lifetime

binge drinking, which is also

demonstrated by a causal

Interaction of stress and methylation with gray matter volume. We examined the interaction of stress and methylation with brain structure and found an interaction of the frequency of negative stressful life events and cg01395541 methylation with gray matter volume in the right caudal cuneus gyrus (T=3.718, p=0.000225; p=0.0482, Bonferroni-corrected) (Figure 2C). This interaction was significant for both boys (T=2.268, p=0.024) and girls (T=2.840, p=0.005). Additionally, we found that this region was smaller in participants who engaged in a high frequency of smoking or drinking compared with those who did not consume alcohol or nicotine (t=-1.989, p=0.048).

Blood-brain methylation association. To examine the consistency of *SPDEF* methylation across blood and brain, we used the online Blood Brain DNA Methylation Comparison Tool. Our blood-based methylation at site cg01395541 was highly correlated with methylation in all brain regions for which data were available, in particular the prefrontal cortex (r=0.991), entorhinal cortex (r=0.981), superior temporal gyrus (r=0.989), and cerebellum (r=0.989) (Figure 3). This suggests that methylation at cg01395541 was highly consistent across blood and brain tissues. However, we were not able to test this relationship experimentally, because there are insufficient numbers of adolescent postmortem brains available.

SPDEF Methylation and Gene Expression

To explore the relationship between methylation at the CpG site cg01395541 and gene expression, we performed a methylation-eQTL analysis. Although there was no association between methylation at cg01395541 and *SPDEF cis*-gene expression, we found an association of methylation with expression of multiple *trans*-genes (for further details, see Table S2 in the online supplement). A total of 246 probes mapping 159 genes associated with methylation levels at cg01395541 for genotypes GG and GA were found (p<0.01) (for further details, see Table S2 in the online supplement).



FIGURE 2. Results of interaction analyses^a

Using DAVID, we found an overrepresentation of gene networks associated with opioid-related disorders (p=0.0023), alcoholism (p=0.012), and tobacco use disorder (p=0.037) (for further details, see Table S3 in the online supplement). The genes for the mu opioid (OPRM1) and dopamine (DRD2) receptors, two genes previously associated with substance use disorders, were present in all of these enriched pathways.

To assess the physical interaction between the SPDEF promoter region and the identified trans-genes, we conducted intra- and interchromosomal interactions between our SPDEF differentially methylated region and the genes listed in Table S2 in the online supplement using the Hi-C browser. We found that SPDEF was physically linked to 12 genes (for further details, see Figure S3 in the online supplement), including DRD2, present in gene networks associated with alcohol dependence and immune response, suggesting that SPDEF could be involved in the regulation of expression of these trans-genes.

DISCUSSION

We conducted a genome-wide methylation study to investigate the effect of psychosocial stress exposure on DNA methylation in the population-based IMAGEN cohort of 14-year-old adolescents. We identified differential methylation in a novel gene, SPDEF, associated with psychosocial stress exposure. By dividing the IMAGEN cohort into an exploratory sample and a test sample (28), we showed and replicated an association of SPDEF methylation at the CpG site cg01395541 with lifetime binge drinking and lifetime smoking. We did not find an association between SPDEF methylation and lifetime alcohol consumption, likely because of the young age of the study participants, resulting in lifetime consumption being a limited measure: more than 60% reported consuming alcohol on less than 10 occasions in their lifetime. There was an interaction of SPDEF methylation and lifetime stress with gray matter volume in the right caudal cuneus. Cuneus volume was negatively correlated with the frequency of drinking and smoking. Furthermore, we found that SPDEF methylation moderated the relationship between psychosocial stress exposure and substance use. Our methylation-eQTL analysis suggests that SPDEF is involved in biological pathways linking psychosocial stress and substance abuse.

SPDEF is an ETS (E26 transformation-specific) transcription factor that has been previously linked to various

^a Panel A shows the interaction of the frequency of negative stressful life events and single-nucleotide polymorphism genotype with cg01395541 methylation. Panel B shows the interaction of the frequency of negative stressful life events and cg01395541 methylation with lifetime frequency of binge drinking. Panel C shows the interaction of the frequency of negative stressful life events and cg01395541 with gray matter volume in the right caudal cuneus gyrus.





^a Configured using the Blood Brain DNA Methylation Comparison Tool. CER=cerebellum, EC=entorhinal cortex, PFC=prefrontal cortex, STG=superior temporal gyrus.

cancers (29) and was reported to be an androgenindependent transactivator of prostate-specific androgen promoter (30). This study is the first, to our knowledge, to implicate *SPDEF* in stress response and substance abuse. The identified differentially methylated region was located in the promoter region of the gene, and further analysis on the sequence revealed that it harbors a potential YY1 binding sequence. Although we found no association between *SPDEF* tionship. Various studies have also reported that early visual processing areas, such as the cuneus, are affected by the reward history of stimuli (36). One possible interpretation is that the cuneus is more susceptible to value-based modulation in individuals with higher stress-induced *SPDEF* methylation, which may increase the risk of substance abuse. In addition, the occipital lobe, which includes the cuneus, has been consistently reported to be involved in stress- and

methylation and its gene ex-

pression in our blood-based

sample, several associations

with *trans*-genes were evident. An enrichment analysis

resulted in an overrepresen-

tation of genes involved in

opioid-related disorders, al-

coholism, and tobacco use

disorder. Genes such as *OPRM1* and *DRD2* have been

extensively studied and found

to influence the endogenous opioid system (31) and dopa-

mine regulation (32), which

are known to be involved in addiction (33). Furthermore, we found that the *SPDEF*

promoter region also physi-

cally interacted with DRD2,

suggesting an involvement of

SPDEF in the regulation of

expressed in the brain and

liver, the two principal or-

gans affected by alcohol

abuse (34). Although we can-

not rule out the possibility

that the effect of *SPDEF* methylation on substance use

is liver dependent, we found

an interaction of SPDEF

methylation and psychoso-

cial stress with the right cau-

dal cuneus gyrus. An inverse

relationship between positron emission tomography-

DRD2 receptor availability

and functional MRI activation in the cuneus has been

observed previously (35).

It is tempting to speculate

that stress-induced SPDEF

methylation may influence

dopaminergic neurotransmission and affect this rela-

SPDEF is highly expressed in the prostate but is also

DRD2 gene expression.

anxiety-related conditions, especially in females (37, 38), but the neurophysiological correlates of these observations remain to be elucidated.

Lastly, we found that *SPDEF* methylation at site cg01395541 is allele-specific. In our sample, individuals with the *SPDEF* risk genotype (GG and GA) showed greater variability in DNA methylation, psychosocial stress exposure, and substance-related behaviors. This is consistent with the idea of differential susceptibility, whereby individuals with particular genetic factors may be more vulnerable to their environment (39). We found and replicated a gene-environment interaction of stress and SNP with *SPDEF* methylation, suggesting that adolescents who harbor the minor allele are more sensitive to psychosocial stress exposure and may have a higher risk of developing substance use behaviors compared with adolescents with an allele type incapable of becoming methylated (AA homozygotes).

Although complex traits are polygenic, a limitation of our study is that a single gene was identified. This was likely a result of noise limitations inherent in genome-wide analyses, which only allowed for SPDEF to reach statistical significance. However, the identification of SPDEF is important because it enabled us to distinguish potential novel mechanisms underlying the risk for substance use. We were unable to detect clear gender effects because of the limited sample size. It is therefore possible that we did not identify additional potential mechanisms related to the androgenic function of the gene. We were able to measure methylation and gene expression only in peripheral blood, although it has become increasingly clear that individual variance in methylation across tissues can be conserved (40). The high correlation between blood-based SPDEF methylation and brain tissues $(r^2>0.8)$ indicates that *SPDEF* can be viewed as a potential biomarker for risk of developing substance abuse (23). Yet these harmonized changes in methylation may not have synonymous effects on gene expression (41), allowing for the possibility of a cis effect on SPDEF expression in the brain.

In summary, our findings describe a novel epigenetic mechanism that helps explain how psychosocial stress exposure influences adolescent substance abuse, thus providing evidence of variations in DNA methylation mediating the effect of environmental influences on psychiatric symptoms and disorders.

AUTHOR AND ARTICLE INFORMATION

The Centre for Population Neuroscience and Stratified Medicine and SGDP Centre, Institute of Psychiatry, King's College London (Tay, Macare, Ruggeri, Jia, Chu, Biondo, Ing, Quinlan, Desrivières, Barker, Schumann); the Department of Biochemistry and Molecular Biology, MOE Key Laboratory of Metabolism and Molecular Medicine, School of Basic Medical Sciences, Fudan University, Shanghai, China (Liu); the Institute of Science and Technology of Brain-Inspired Intelligence, Fudan University, Shanghai, China (Jia); the Key Laboratory of Computational Neuroscience and Brain-Inspired Intelligence, Fudan University, Ministry of Education, Shanghai, China (Jia); the School of Life Sciences and Institute of Science and Technology for Brain-Inspired Intelligence, Fudan University, Shanghai, China (Luo); Uppsala University, Uppsala, Sweden (Sarkysian, Bakalkin); the Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany (Banaschewski, Hohmann); the Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology, and Neuroscience, King's College London (Barker); the Discipline of Psychiatry, School of Medicine and Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin (Bokde, Nees); University Medical Centre Hamburg-Eppendorf, Hamburg, Germany (Bromberg, Büchel); the Department of Cognitive and Clinical Neuroscience, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany (Flor, Nees); the Department of Psychology, School of Social Sciences, University of Mannheim, Mannheim, Germany (Flor); the Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany (Nees); the German Research Foundation, Bonn, Germany (Nees); NeuroSpin, Université Paris-Saclay, Gif-sur-Yvette, France (Frouin, Orfanos); the Departments of Psychiatry and Psychology, University of Vermont, Burlington (Garavan); Sir Peter Mansfield Imaging Centre School of Physics and Astronomy, University of Nottingham, Nottingham, United Kingdom (Gowland); the Department of Psychiatry and Psychotherapy, Campus Charité Mitte, Charité, Universitätsmedizin Berlin, Berlin (Heinz, Walter); Physikalisch-Technische Bundesanstalt, Braunschweig and Berlin, Berlin (Itterman); the Institut National de la Santé et de la Recherche Médicale, INSERM Unit 1000 "Neuroimaging & Psychiatry," DIGITEO Labs, University Paris Sud-Paris Saclay, University Paris Descartes, Gif sur Yvette, France (Martinot); the Maison de Solenn, Cochin Hospital, Paris, France (Martinot); the Institut National de la Santé et de la Recherche Médicale, University Paris Sud-University Paris Saclay, DIGITEO Labs, Gif sur Yvette, France (Artiges); the Department of Psychiatry, Orsay Hospital, Orsay, France (Artiges); the Bloorview Research Institute, Holland Bloorview Kids Rehabilitation, Hospital and Departments of Psychology and Psychiatry, Bloorview Research Institute, University of Toronto, Toronto (Paus); the Department of Child and Adolescent Psychiatry and Psychotherapy, University Medical Center Göttingen, Göttingen, Germany (Poustka); the Clinic for Child and Adolescent Psychiatry, Medical University of Vienna, Vienna (Poustka); the Department of Psychiatry and the Neuroimaging Center, Technische Universität Dresden, Dresden, Germany (Fröhner, Smolka); the School of Psychology and the Global Brain Health Institute, Trinity College Dublin, Dublin (Whelan); the Department of Psychiatry, Social Psychiatry, and Psychotherapy, Hannover Medical School, Hannover, Germany (Frieling, Bleich); the Department of Medical Sciences, Molecular Medicine and Science for Life laboratory, Uppsala University, Uppsala, Sweden (Syvänen); and the Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institutet, Stockholm (Rüegg, Ekström).

Address correspondence to Dr. Schumann (gunter.schumann@kcl.ac.uk).

Ms. Tay and Drs. Macare, Liu, Ruggeri, Rüegg, Ekström, Bakalkin, and Schumann contributed equally to this article.

Supported by the European Union FP6 Integrated Project IMAGEN (grant LSHM-CT-2007-037286); the Horizon 2020 ERC Advanced Grant "STRATIFY" (grant 695313); ERANID (Understanding the Interplay Between Cultural, Biological, and Subjective Factors in Drug Use Pathways) (grant PR-ST-0416-10004); BRIDGET (JPND: Brain Imaging, Cognition, Dementia, and Next Generation Genomics) (grant MR/N027558/1); FP7 projects IMAGEMEND (IMAging GEnetics for MENtal Disorders) (grant 602450) and MATRICS (grant 603016); the Innovative Medicine Initiative Project EU-AIMS (grant 115300-2); the Medical Research Council Grant c-VEDA (Consortium on Vulnerability to Externalizing Disorders and Addictions) (grant MR/N000390/1); the Swedish Research Council FORMAS; the Medical Research Council; the National Institute for Health Research Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London; the Bundesministeriumfür Bildung und Forschung (grants 01GS08152, 01EV0711, eMED SysAlc01ZX1311A, and Forschungsnetz AERIAL); the Deutsche Forschungsgemeinschaft (grants SM 80/7-1, SM 80/7-2, and SFB 940/1); ANR (grants AF12-NEUR0008-01-WM2NA and ANR-12-SAMA-0004); the Fondation de France; the Fondation pour la Recherche Médicale; the Mission Interministérielle de Lutte contre les Drogues et les Conduites Addictives; the Fondation pour la Recherche Médicale (grant DPA20140629802); the Fondation de l'Avenir, Paris Sud University IDEX 2012; NIH; Science Foundation Ireland (grant 16/ERCD/3797 (Axon, Testosterone, and Mental Health During Adolescence) (grant RO1 MH085772-01A1); and the NIH Consortium (grant U54 EB020403).

Dr. Banaschewski has served as an adviser or consultant for Actelion, Hexal Pharma, Lilly, Lundbeck, Medice, Novartis, and Shire; he has received conference support or speaking fees from Lilly, Medice, Novartis, and Shire; he has participated in clinical trials conducted by Shire and Vifor Pharma; he has received royalties from CIP-Medien, Hogrefe, Kohlhammer, and Oxford University Press. Dr. Walter has received a speaker honorarium from Servier, and he has received grant support from the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG, FOR 1617, grant WA 1539/7-1). The other authors report no financial relationships with commercial interests.

Received December 15, 2017; revisions received May 15 and June 23, 2018; accepted June 29, 2018; published online Dec. 11, 2018.

REFERENCES

- 1. Agid O, Kohn Y, Lerer B: Environmental stress and psychiatric illness. Biomed Pharmacother 2000; 54:135–141
- Paus T, Keshavan M, Giedd JN: Why do many psychiatric disorders emerge during adolescence? Nat Rev Neurosci 2008; 9: 947–957
- Fisher PA, Beauchamp KG, Roos LE, et al: The neurobiology of intervention and prevention in early adversity. Annu Rev Clin Psychol 2016; 12:331–357
- Casement MD, Shaw DS, Sitnick SL, et al: Life stress in adolescence predicts early adult reward-related brain function and alcohol dependence. Soc Cogn Affect Neurosci 2015; 10: 416–423
- 5. Jaenisch R, Bird A: Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 2003; 33(suppl):245–254
- Cadet JL: Epigenetics of stress, addiction, and resilience: therapeutic implications. Mol Neurobiol 2016; 53:545–560
- Barker ED, Walton E, Cecil CAM: Annual Research Review: DNA methylation as a mediator in the association between risk exposure and child and adolescent psychopathology. J Child Psychol Psychiatry 2018; 59:303–322
- Taqi MM, Bazov I, Watanabe H, et al: Prodynorphin CpG-SNPs associated with alcohol dependence: elevated methylation in the brain of human alcoholics. Addict Biol 2011; 16: 499–509
- 9. Parira T, Laverde A, Agudelo M: Epigenetic interactions between alcohol and cannabinergic effects: focus on histone modification and DNA methylation. J Alcohol Drug Depend 2017; 5:259
- Karoly HC, Thayer RE, Hagerty SL, et al: TLR4 methylation moderates the relationship between alcohol use severity and gray matter loss. J Stud Alcohol Drugs 2017; 78:696–705
- Andersen AM, Dogan MV, Beach SR, et al: Current and future prospects for epigenetic biomarkers of substance use disorders. Genes (Basel) 2015; 6:991–1022
- 12. Tyrka AR, Parade SH, Welch ES, et al: Methylation of the leukocyte glucocorticoid receptor gene promoter in adults: associations with early adversity and depressive, anxiety and substance-use disorders. Transl Psychiatry 2016; 6:e848
- Sullivan PF: The Psychiatric GWAS Consortium: big science comes to psychiatry. Neuron 2010; 68:182–186

- 14. Schumann G, Loth E, Banaschewski T, et al: The IMAGEN study: reinforcement-related behaviour in normal brain function and psychopathology. Mol Psychiatry 2010; 15:1128–1139
- Jaffe AE, Murakami P, Lee H, et al: Bump hunting to identify differentially methylated regions in epigenetic epidemiology studies. Int J Epidemiol 2012; 41:200–209
- 16. Bock C: Analysing and interpreting DNA methylation data. Nat Rev Genet 2012; 13:705–719
- Newcomb MD, Huba GJ, Bentler PM. A multidimensional assessment of stressful life events among adolescents: derivation and correlates. 1981:400–415
- Andersson HB: The ESPAD Report: Alcohol and Other Drug Use Among Students in 35 European Countries. Stockholm, Modintryckoffset AB, 2003
- Illumina: Infinium HumanMethylation450 BeadChip. San Diego, Illumina, 2012. https://www.illumina.com/content/dam/illuminamarketing/documents/products/datasheets/datasheet_humanmethylation450.pdf
- 20. IBM: IBM SPSS Statistics for Windows. Armonk, NY, IBM, 2011
- 21. Aryee MJ, Jaffe AE, Corrada-Bravo H, et al: Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. Bioinformatics 2014; 30: 1363–1369
- Daca-Roszak P, Pfeifer A, Zebracka-Gala J, et al: Impact of SNPs on methylation readouts by Illumina Infinium HumanMethylation450 BeadChip Array: implications for comparative population studies. BMC Genomics 2015; 16:1003
- Hannon E, Lunnon K, Schalkwyk L, et al: Interindividual methylomic variation across blood, cortex, and cerebellum: implications for epigenetic studies of neurological and neuropsychiatric phenotypes. Epigenetics 2015; 10:1024–1032
- 24. Shabalin AA. Matrix eQTL: ultra fast eQTL analysis via large matrix operations. 2012; 28:1353–1358
- Huang da W, Sherman BT, Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4:44–57
- 26. Wang Y, Zhang B, Zhang L, et al: The 3D Genome Browser: a web-based browser for visualizing 3D genome organization and long-range chromatin interactions. Gonome Biol 2018; 19: 151
- 27. Roessler J, Ammerpohl O, Gutwein J, et al: Quantitative cross-validation and content analysis of the 450k DNA methylation array from Illumina, Inc. BMC Res Notes 2012; 5: 210–210
- Sleiman PMA, Wang ML, Cianferoni A, et al: GWAS identifies four novel eosinophilic esophagitis loci. Nat Commun 2014; 5: 5593
- 29. Mahajan N: Signatures of prostate-derived ETS factor (PDEF) in cancer. Tumour Biol 2016; 37:14335–14340
- 30. GeneCards: The Human Gene Database v4.5.0 Build 25. 2017. http://www.genecards.org/
- Mague SD, Blendy JA: OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models. Drug Alcohol Depend 2010; 108:172–182
- 32. Quilter CR, Gilbert CL, Oliver GL, et al: Gene expression profiling in porcine maternal infanticide: a model for puerperal psychosis. Am J Med Genet B Neuropsychiatr Genet 2008; 147B: 1126–1137
- 33. Nestler EJ: Is there a common molecular pathway for addiction? Nat Neurosci 2005; 8:1445–1449
- Quertemont E: Genetic polymorphism in ethanol metabolism: acetaldehyde contribution to alcohol abuse and alcoholism. Mol Psychiatry 2004; 9:570–581
- 35. Tomasi D, Wang GJ, Volkow ND: Association between striatal dopamine D2/D3 receptors and brain activation during visual attention: effects of sleep deprivation. Transl Psychiatry 2016; 6: e828

- Yalachkov Y, Kaiser J, Naumer MJ: Sensory and motor aspects of addiction. Behav Brain Res 2010; 207:215–222
- Feldker K, Heitmann CY, Neumeister P, et al: Transdiagnostic brain responses to disorder-related threat across four psychiatric disorders. Psychol Med 2017; 47:730–743
- Seo D, Ahluwalia A, Potenza MN, et al: Gender differences in neural correlates of stress-induced anxiety. J Neurosci Res 2017; 95:115–125
- 39. Belsky J, Bakermans-Kranenburg M, van IJzendoorn MH: For better and for worse. Curr Dir Psychol Sci 2007; 16:300–304
- 40. Mill J, Davies M, Volta M, et al: Methylomic profiling across brain and blood: Brain area-specific differentially methylated regions, individual differences, and allele-specific DNA methylation, Presented at proceedings of the 12th International Congress of Human Genetics/61st Annual Meeting of the American Society of Human Genetics, October 12, 2011, Montreal
- Fan S, Zhang X: CpG island methylation pattern in different human tissues and its correlation with gene expression. Biochem Biophys Res Commun 2009; 383:421–425